Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1128-33. doi: 10.1016/j.bmcl.2009.12.014. Epub 2009 Dec 6.

Abstract

Agonists of the 5-HT(2C) receptor have been shown to suppress appetite and reduce body weight in animal models as well as in humans. However, agonism of the related 5-HT(2B) receptor has been associated with valvular heart disease. Synthesis and biological evaluation of a series of novel and highly selective dihydroquinazolinone-derived 5-HT(2C) agonists with no detectable agonism of the 5-HT(2B) receptor is described. Among these, compounds (+)-2a and (+)-3c were identified as potent and highly selective agonists which exhibited weight loss in a rat model upon oral dosing.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Anti-Obesity Agents / administration & dosage
  • Anti-Obesity Agents / chemistry*
  • Anti-Obesity Agents / metabolism
  • Eating / drug effects
  • Eating / physiology
  • Humans
  • Male
  • Obesity / drug therapy*
  • Obesity / metabolism
  • Protein Binding / physiology
  • Quinazolinones / administration & dosage
  • Quinazolinones / chemistry*
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Serotonin, 5-HT2C / metabolism
  • Serotonin 5-HT2 Receptor Agonists*
  • Serotonin Receptor Agonists / administration & dosage
  • Serotonin Receptor Agonists / chemistry*
  • Serotonin Receptor Agonists / metabolism

Substances

  • Anti-Obesity Agents
  • Quinazolinones
  • Receptor, Serotonin, 5-HT2C
  • Serotonin 5-HT2 Receptor Agonists
  • Serotonin Receptor Agonists